Navigation Links
Cancer diagnosis isotopes from Garching

This release is available in German.

The German Federal Ministry of Health has awarded more than one million euros in research and development funding for the efficient production of an important cancer diagnostic agent at the research neutron source FRM II. In a 2009 feasibility study, the Technische Universitaet Muenchen demonstrated that due to the high neutron flux the neutron source in Garching can produce about half of the European demand of the radioisotope molybdenum-99.

Approximately seventy thousand patients undergo scintigraphic tests every day throughout the world. About 70 percent of these tests are performed with technetium-99m for the diagnosis of tumors. Necessary for the production of technetium-99m is its parent isotope molybdenum-99, most of which is produced in just five neutron sources worldwide. If production at one of these sources temporarily pauses, vital investigations have to be postponed. Therefore nuclear medicine physicians have long been calling for an upgrade of the Garching research neutron source for production of molybdenum-99.

Now the Federal Health Ministry has pledged to support the development of an efficient radiation process at Garching's research neutron source. Subsidies amounting to one million euros are allocated for the years 2011 and 2012. In addition, the State of Bavaria is supporting the construction with 1.2 million euros for personnel and material resources.

During the current ongoing maintenance and upgrading work, the FRM II has already installed a thimble in which the molybdenum-99 will be produced in the future. The aim of further research is to produce significantly higher specific activity than existing production facilities. This includes not only measures for efficient cooling of the material in a position with highest neutron flux, but also more efficient packaging processes for safe and speedy delivery of the short-lived isotope for further radiopharmaceutical processing.

The Scientific Director of the FRM II, Prof. Dr. Winfried Petry, said: "The funding helps us to develop more efficient methods for the production of the isotope. Therewith Germany provides an important contribution to Europe's supply of radioisotopes for nuclear medicine."

Already in clinical use, there is another isotope that is produced at TUM's neutron source, lutetium-177. It is mainly used to treat endocrine tumors such as gastrointestinal tumors. In cooperation with the firm Isotope Technologies Garching GmbH (ITG), the research neutron source produces lutetium-177 for the treatment of about 50 patients per week.


Contact: Dr. Andreas Battenberg
Technische Universitaet Muenchen

Related medicine news :

1. Duke team finds new clues to how cancer spreads
2. Nearly Half of Older Breast Cancer Patients Dont Get Radiation
3. Scientists identify a novel mechanism for evolution of highly aggressive cancers
4. Many advanced breast cancer patients do not receive recommended treatment
5. Lifestyle Changes Might Alter Breast Cancer Rates
6. New breast cancer risk model quantifies the impact of risk reduction
7. Hereditary colon cancer syndrome marked by abnormally dense blood vessel growth in mouth
8. UH Cancer Center receives $3.58 million gift for mesothelioma research
9. New insights into origin of deadly cancer
10. Marriage Might Boost Colon Cancer Survival
11. Leftover embryonic cells connect gastric reflux and cancer
Post Your Comments:
Related Image:
Cancer diagnosis isotopes from Garching
(Date:11/25/2015)... ... ... Today, Mothers Against Drunk Driving (MADD) learned that the number of ... time since 2011. In 2014, there were 9,967 fatalities involving an alcohol impaired driver, ... Traffic Safety Administration (NHTSA), 32,675 people were killed in traffic crashes in 2014. Drunk ...
(Date:11/25/2015)... ... November 25, 2015 , ... In honor ... Periwinkle Pioneers, individuals and groups responsible for advancing care for pulmonary hypertension (PH) ... nominated by the public, will receive special recognition throughout 2016 as part of ...
(Date:11/25/2015)... ... 25, 2015 , ... Privately owned Contract Development and Manufacturing ... its current state of the art research, development and manufacturing facility outside of ... manufacturing capacity as well as to support its clients’ growing research and development ...
(Date:11/25/2015)... ... November 25, 2015 , ... Many people know of ... weight gain, cold hands, and dry skin. But many people who find their cholesterol ... exercise regimen instead of their thyroid, especially if they don’t have any of the ...
(Date:11/25/2015)... ... November 25, 2015 , ... Since its launch in ... involving adult stem cell therapies to patients with chronic degenerative medical conditions. Now, ... a Registered Trademark (RTM). , Organizations are required to hold a registered trademark ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... , Nov. 25, 2015 Allergan ... pharmaceutical company, and Rugen Therapeutics, a start-up  biotechnology ... for unmet CNS disorders and funded by the ... they have entered into an exclusive collaboration to ... for Autism Spectrum Disorders (ASD) and Obsessive Compulsive ...
(Date:11/25/2015)... Nov. 25, 2015  Mindray Medical ... MR ), a leading developer, ... worldwide, today announced that it will ... of shareholders at the Company,s Hong Kong office ... Prince Edward West Road, Mongkok KL, Hong ...
(Date:11/25/2015)... , November 25, 2015 /PRNewswire/ ... announced the addition of the  "Global ...  report to their offering.  ... the addition of the  "Global Drug ...  report to their offering.  --> ...
Breaking Medicine Technology: